You Are Invited to a VIRTUAL CME/CPE/CNE SYMPOSIUM

Jointly provided by     This activity is supported by independent educational grants from Bristol-Myers Squibb and Merck & Co., Inc. Virtual Symposium Date Tuesday, April 21, 2020 5:00 PM - 7:00 PM ET Click Here to Complete Your Evaluation and Download Your Certificate To join a webcast or complete an evaluation for a webcast you attended, please visit us at https://www.pathlms.com/impacteducation   Learn About Latest trial results on checkpoint inhibitors and CAR-T therapies MOA of novel immuno-oncology agents Key outcome measures and payment models in immuno-oncology   Expert Faculty Presenters Yung Lyou, MD, PhD Oncologist Assistant Clinical Professor, Department of Medical Oncology City of Hope Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC   Who Should Attend? This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP 2020 Managed Care and Specialty Pharmacy Annual Meeting.   Statement of Need/Program Overview The advent and rapid escalation of targeted cancer therapies has led to the emergence of sophisticated immuno-oncology agents. However, the historically high cost of these agents has compelled payers to initiate strategies to control utilization and manage costs. Because of the explosive growth of this category and their corresponding budgetary impact, healthcare decision makers (HCDMs) and managed care professionals require education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments. Furthermore, given increased focus on value-based benefit design, utilization management, and payer-led clinical interventions to address shortfalls in oncology practice, managed care stakeholders also have a need for information to effectively address the evolving paradigm of cancer treatment. This symposium will provide HCDMs and managed care professionals with the required education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments.   Educational Objectives At the conclusion of this activity, participants should be able to demonstrate improved ability to: Characterize the role of the immune system in immunosurveillance and elimination of malignant cell lines Explain the mechanisms of action of novel immuno-oncology agents such as PD-1 and PD-L1 inhibitors and CAR-T therapies Describe key outcomes measures in immuno-oncology and the importance of cumulative assessment of outcomes Apply comprehensive analyses of emerging clinical trial data for checkpoint inhibitors and CAR-T therapies Illustrate current and proposed payer initiatives for the funding and management of checkpoint inhibitors and CAR-T therapies   Agenda Date and Time Tuesday, April 21, 2020 5:00 PM - 7:00 PM ET Pre-Activity Learning Assessment and Opening Comments/Overview Edmund Pezalla, MD, MPH Clinical Update on the Evolving Immuno-Oncology Treatment Paradigm Yung Lyou, MD, PhD Evidence-based Decision Making in a Cost Conscience Environment Edmund Pezalla, MD, MPH Medical and Pharmacy Management Strategies to Enhance Outcomes Requiring Treatment with Immuno-Oncology Agents Edmund Pezalla, MD, MPH Audience Q&A Session Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation Adjournment   Accreditation Information Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Continuing Medical Education The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Continuing Pharmacy Education Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008162-9999-20-1075-L01-P Type of Activity: Application Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Americans with Disabilities Act ♿ Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812. Fee Information No additional fee is required to attend this CME/CPE/CNE activity. If you have any questions, please call (215) 619-8812 or email info@impactedu.net.